Aptose granted Fast Track Designation from FDA for HM43239 in relapsed/refractory AML patients and FLT3 Mutation

Orca-T improves AML survival in phase Ib trial subgroup

Orca Bio will present new data at the 2024 American Society of Clinical Oncology Annual Meeting in Chicago.

May 24, 2024

Older adults with aggressive blood cancer are responsive to treatment and show prolonged survival

Standard of care treatment for acute myeloid leukemia is safe and effective for adults over 80, according to a study published in Blood Neoplasia. For roughly a quarter of patients, this treatment can durably prolong survival.

May 17, 2024

Vol.50 No.20

Clinical Roundup

Lower MRD prior to HCT associated with better outcomes in FLT3-ITD AML

Patients in remission after being treated for a high-risk blood cancer are likely to have better outcomes if no trace of the cancer is detectable before the patients receive donor blood cells.

May 03, 2024

Vol.50 No.18

Drugs & Targets

Mission Bio develops single-cell MRD assay

Mission Bio has developed a single-cell measurable residual disease assay that aims to advance personalized healthcare for patients with blood cancer.

September 29, 2023

Vol.49 No.36

Clinical Roundup

Vitamin C, D supplements led to fewer complications in AML, no OS benefit

Patients with acute myeloid leukemia who received vitamin C and D supplements while undergoing intensive chemotherapy had lower rates of complications, such as infections, bleeding, and inflammation, when compared with similar, previously treated patients who did not receive these supplements.

September 15, 2023

Vol.49 No.34